CG oncology Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares.

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BrightSpring Health Services Inc

American Healthcare REIT Inc., Fortegra Group Inc. and Fractyle Health Inc. set proposed price ranges in their upcoming initial public offerings on Monday, after a mixed reception to two deals late last week.

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Seven IPOs priced this past week, led by 3 that raised $100+ million. Four very small Chinese issuers also began trading in the US this past week, all raising $10 million or less.

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech stocks have fallen about 1% so far this year.

Biotech's First IPO of 2024 Popped 96%. What It Means.

With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressable market (NMIBC) where there is an urgent need for safer, more widely available treatment options. The current standard of care treatment, the BCG vaccine, is in short supply and currently being rationed.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

CG Oncology valued at $1.75 bln in strong market debut

Cancer drug company CG Oncology Inc. priced its initial public offering above its estimated range and added three million shares to the deal in a bullish sign ahead of its trading debut Thursday on the Nasdaq.

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering.

CG Oncology Announces Pricing of Upsized Initial Public Offering

News for CG oncology Inc Stock (CGON)